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Abstract
Background: Malva verticillata seeds are used as a therapeutic medicine to treat kidney dysfunction in traditional
Chinese medicine (TCM). TCM has suggested that herbal medicine tonifying kidney function may have beneficial
effect on bone metabolism.
Methods: Osteoclastogenesis was examined in bone marrow macrophages by measuring tartrate-resistant acid
phosphatase (TRAP) activity and counting the number of TRAP-stained multinuclear cells. The activation of receptor
activator of nuclear factor-kB (RANK) ligand signaling, and the expression of c-Fos and nuclear factor of activated
T-cells, cytoplasmic 1 (NFATc1) were investigated by western blot analysis. Transcription factor and bone resorption
marker mRNA levels were evaluated using real-time quantitative polymerase chain reaction. The bone resorption
activity of mature osteoclast was examined in osteoclasts cultured on a hydroxyapatite-coated culture plate.
Results: A water extract of M. verticillata seeds (WEMV) inhibited osteoclastogenesis stimulated by RANKL. WEMV
also strongly inhibited expression of c-Fos and NFATc1 as well as phosphorylation of c-Jun N-terminal kinase, p38,
I-kBα, and phospholipase γ2. Furthermore, WEMV significantly attenuated osteoclast resorption activity and
downregulated mRNA expression of resorption markers.
Conclusion: These results demonstrate that WEMV inhibits osteoclastogenesis and bone resorption by suppressing
the RANKL signaling pathway and suggest that M. verticillata seeds may be used as a therapeutic candidate in
complementary alternative medicine to treat pathological bone diseases.
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Background
Osteoporosis is a skeletal disorder characterized by low
bone mineral density and deteriorated bone microstruc-
ture, which increases the incidence of bone fracture. It is
caused mainly by an imbalance between bone resorption
and bone formation when an increased rate of bone re-
sorption overcomes a decreased rate of bone formation
caused by estrogen deficiency, aging, or an inadequate
intake of calcium or vitamin D3, especially in elderly
populations [1, 2]. Receptor activator for nuclear factor-
kB (RANK) ligand (RANKL) is a cytokine that is essen-
tial for osteoclast differentiation, regulation of osteoclast
bone resorbing activity and osteoclast apoptosis [3].
RANKL activates various signaling molecules and critical
transcription factors in osteoclastogenesis such as
mitogen-activated protein kinase (MAPK) and nuclear
factor of activated T-cells, cytoplasmic 1 (NFATc1). Re-
cent studies have investigated the molecular mechanism
of osteoclastogenesis and bone resorption to develop
anti-osteoporosis agents with fewer undesirable side ef-
fects [4, 5]. Herbal medicine and natural products have
recently been suggested to mitigate bone loss and ameli-
orate osteoporosis with fewer side effects through their
ability to affect bone cells [6–8].
Malva verticillata Linn is a species of the mallow
genus Malva in the family of Malvaceae [9]. Seeds of M.
verticillata, commonly known as Dong Kui Zi or
Donggyuja, have been used to enhance kidney strength,
remove renal stones, and treat chronic mastitis and hypo-
galactia in traditional Chinese medicine (TCM) [9, 10]. M.
verticillata seeds contain various polysaccharides and
flavonoids with a number of pharmacological activities in-
cluding hypoglycemic activity [11–13]. In TCM, herbal
medicine is used to invigorate kidney function so as to
strengthen musculoskeletal organs such as bone [14, 15].
Chinese herbal formulas or herbal medicines prescribed in
TCM to nourish or replenish kidney function have been
shown to have a positive effect on ovariectomy-induced
osteoporosis [16] and a pharmaceutical effect on bone by
regulating osteoclast differentiation [17] or mast cell activ-
ity [18]. Based on the results of these studies, M. verticil-
lata seeds used in TCM to stimulate kidney function
might have a beneficial effect on bone by regulating bone
cell differentiation; however, no study has explored the ef-
fect of M. verticillata seeds on bone cell differentiation
and/or function.
In this study, we examined whether a water extract
of M. verticillata seeds (WEMV) exerts a pharmaceut-
ical effect to regulate osteoclastogenesis or osteogen-
esis. We found that WEMV inhibited RANKL-induced
osteoclastogenesis, but WEMV had no effect on bone
morphogenetic protein-2 (BMP-2)- or ascorbic acid/β-
glycerophosphate-induced osteogenesis. To increase our
understanding of the molecular mechanism underlying
WEMV activity in osteoclastogenesis and bone resorption,
we investigated the effect of WEMV on RANKL signaling
and the expression of genes involved in bone resorption.
Methods
Preparation of a water extract of M. verticillata seeds
M. verticillata seeds (Yeongcheon herb, Korea) were
authenticated by Prof. K.H. Bae (Chungnam National
University, Korea). A voucher specimen with registration
number 221 is maintained in the herbarium of the KM
Application Center at the Korea Institute of Oriental
Medicine. Dried M. verticillata seeds (50 g) were ex-
tracted by boiling in distilled water (1 L) for 3 h as
described previously [19]. The water extract of M. verti-
cillata seeds (WEMV) was filtrated using standard sieves
(150 μm), concentrated by lyophilization, and stored at
–20 °C until use. A WEMV stock solution was prepared
by dissolving the lyophilized powder in distilled water
followed by filtering through a 0.2 μm syringe filter. The
yield of dried extract from the staring materials was ap-
proximately 8.96 % (w/w).
Gas chromatography/ mass spectrometry analysis
The lyophilized water extract of M. verticillata seeds
was submitted to separation through gas chromatog-
raphy with detection by mass spectrometry (GC/MS).
The analysis was performed in a GC/MS system (Agilent
Technologies, Atlanta, GA, USA) using DB-5 MS
capillary column (30 m × 0.25 mm × 0.25 μm). Chroma-
tographic conditions were as follows: the extract (1 μL)
was injected in split mode with a ratio of 1/20 at 350 °C,
oven initial temperature was 70 °C during 1 min,
followed by heating at a rate of 5 °C/min at 300 °C, and
totally run for 67 min. The mass analyzer was set to scan
from 10 to 800 atomic mass unit. β-sitosterol was used
as standard marker for GC/MS analysis. Peak identifica-
tion was carried out comparison of the experimental
mass spectrum in the National Institute of Standards
and Technology (NIST) and Wiley GC-MS libraries.
Fourteen components, including 1,3-dihydroxyacetone
dimer, d-alanine, 5-hydroxymethyl furfural, 2-hydroxy-
gamma-butyrolactone, palmitic acid, oleamide, and β-
sitosterol, were identified in WEMV (data not shown).
Cell culture
Mouse bone marrow macrophages (BMMs) were ob-
tained from mouse bone marrow cells (BMCs) as
described previously [20]. For osteoclast differentiation,
BMMs (1 × 104 cells/well, 96-well plate) were cultured
in α-MEM differentiation medium containing 60 ng/mL
of macrophage colony stimulating factor (M-CSF) and
100 ng/mL of RANKL for 4 days. Tartrate-resistant acid
phosphatase (TRAP)-positive stained cells with more than
three nuclei were counted as multinuclear osteoclasts
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[TRAP (+) MNCs]. For osteoblast differentiation, C2C12
cells (ATCC, USA) were cultured (1 × 104 cells/well, 96-
well plate) in α-MEM differentiation medium containing
100 ng/mL of BMP-2 for 3 days. Primary calvarial osteo-
blasts (5 × 104 cells/well, 48-well plate) obtained as
described previously [21] were cultured in α-MEM dif-
ferentiation medium containing 50 μg/mL ascorbic
acid and 10 mM β-glycerophosphate for 5 days. BMMs
were cultured in α-MEM proliferation medium, and
C2C12 cells and osteoblasts were cultured in DMEM
proliferation medium containing various concentra-
tions of WEMV for 2 days to examine cytotoxicity
using a CCK-8 assay (Dojindo Molecular Technologies
Inc., Tokyo, Japan). All media contained 10 % fetal
bovine serum (FBS) and antibiotics (100 U/mL penicil-
lin and 100 μg/mL streptomycin) and were replaced at
3-days intervals.
Enzyme assay
TRAP and alkaline phosphatase (ALP) activity assay
were performed as described previously [20]. Briefly,
cells were fixed in 10 % formalin, permeabilized with
0.1 % Triton X-100, and incubated with TRAP assay
buffer (50 mM sodium tartrate, 0.12 M sodium acet-
ate, pH 5.2) with p-nitrophenyl phosphate (1 mg/mL)
or incubated with ALP assay buffer [100 mM sodium
carbonate (pH 10), 1 mM MgCl2, 50 mM Na2CO3]
with naphthol AS-BI phosphate. After a 10-min incu-
bation at 37 °C, the reaction was stopped with stop
solution and the absorbance was measured. MNCs
were stained with TRAP staining buffer containing
naphthol AS-MX phosphate and Fast Red Violet LB
(Sigma-Aldrich).
Western blot analysis
Cells were washed twice with phosphate-buffered saline
(PBS) and total cell lysate was obtained using Radioimmu-
noprecipitation assay (RIPA) buffer (Millipore, MA, USA)
containing protease and phosphatase inhibitors. Protein
concentration was determined using a bicinchoninic acid
assay (BCA) Assay Kit (Thermo Scientific, Rockford, IL,
USA). Total protein (30 μg) was separated by 12.5 % SDS-
PAGE gel electrophoresis, transferred to polyvinylidene
fluoride (PVDF) membrane, and immunoblotted with
specific antibody. Antibodies for MAPK, nuclear factor-
kappaB (NF-kB), or phospholipase C (PLC) signaling pro-
teins (Cell Singling Technology, MA, USA) or c-Fos and
NFATc1 transcription factors (Santa Cruz Biotechnology,
CA, USA) were used in this study. Chemiluminescent
signals were detected using a ChemiDoc imaging system
(Bio-Rad Laboratories, CA, USA) and a chemilumines-
cence reagent (Thermo Scientific).
Real-time quantitative polymerase chain reaction (qRT-PCR)
Total RNA was isolated using an RNAspin total RNA
extraction kit (Intron, Daejeon, Korea). cDNA was
synthesized from 1 μg of total RNA using AccuPower
RT-PreMix (Bioneer, Daejeon, Korea) according to the
manufacturer’s protocol. qRT-PCR analysis was per-
formed using a CFX96 Touch Real-Time PCR System
(Bio-Rad, CA, USA) and AccuPower GreenStar qPCR
Master Mix (Bioneer, Daejeon, Korea). The qRT-PCR re-
actions comprised 40 cycles at 94 °C for 20 s and 60 °C
for 40 s. All reactions were performed in triplicate. The
relative expression levels of target genes were normal-
ized to hypoxanthine phosphoribosyltransferase (HPRT)
expression and analyzed using Bio-Rad CFX Manage 3.1
software (Bio-Rad, CA, USA).
Retrovirus preparation and infection
A pMX-puro-green fluorescent protein (GFP) retrovirus
vector (provided by Dr. T. Kitamura, University of
Tokyo) and a pMX-Ca-NFATc1 vector encoding HA-
tagged Ca-NFATc1, a constitutively expressed form of
NFATc1 provided by Dr. N.A. Clipstone (Northwestern
University), were used for retrovirus preparation as de-
scribed previously [20]. Briefly, to generate retroviral
stocks, the vector was transfected into Plat-E retroviral
packaging cells. BMMs (3 × 106 cells, 100-mm dish)
were infected with retrovirus soup from the packaging
cells by incubation with polybrene (6 μg/mL) for 8 h.
Infected BMMs were selected with puromycin (2 μg/mL,
Sigma-Aldrich) for 5 days. The selected BMMs were cul-
tured in differentiation medium with WEMV for 4 days
and then stained with TRAP-staining solution.
Bone resorption assay
Osteoclasts obtained from a BMCs-osteoblasts cocul-
ture system were cultured on OsteoAssay Surface
plates (Corning, MA, USA). Osteoclasts were preincu-
bated with WEMV for 3 h and further cultured in
differentiation medium for an additional 16 h. After
removing cells, stained osteoclasts and resorbed areas
were observed under an inverted microscope (40×
magnification). The resorption areas were analyzed in
three randomly selected fields of each well using
Image J software.
Statistical analysis
Statistical significance of the differences in TRAP ac-
tivity, MNC number, and mRNA levels of genes was
analyzed using Student’s t-test. Data are presented as
means ± the standard deviation of three independent
experiments. Differences are considered significant at
p < 0.05.
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Results
WEMV inhibits RANKL-induced osteoclast differentiation
in BMMs
We first examined the pharmaceutical effect of WEMV
on osteoclast differentiation. BMMs were cultured in
differentiation medium with or without WEMV for
4 days. As shown in Fig. 1a, RANKL induced differenti-
ation of BMMs into TRAP-positive stained MNCs;
however, WEMV inhibited RANKL-induced TRAP ac-
tivity and MNC formation (p < 0.01) (Fig. 1b and c) in a
dose-dependent manner. WEMV at a concentration of
160 μg/mL almost completely suppressed the MNC
number (9 ± 2, p < 0.01) without inducing cytotoxicity
compared with the control (301 ± 11) (Fig. 1d) suggest-
ing that inhibitory activity of WEMV was specific for
osteoclastogenesis. However, because osteoclastogenesis
involves sequential steps in the differentiation of precur-
sor cells into pre-osteoclast and osteoclasts, the stage of
osteoclastogenesis that was inhibited by WEMV was
unclear. To determine the effect of WEMV on each
stage of osteoclastogenesis, BMMs were cultured with
WEMV (160 μg/mL) at four time points after which
MNC numbers were counted on day 4. We found that
the MNC number was suppressed significantly when
WEMV was added on day 0 (2 ± 1, p < 0.01) or on day 1
(203 ± 2, p < 0.01) as compared with the control (275 ±
22) (Fig. 1e), but MNC formation was not inhibited by
WEMV when added on days 2 or 3 suggesting that
WEMV inhibits early osteoclast differentiation.
WEMV does not affect osteoblast differentiation
BMP-2 and ascorbic acid/β-glycerophosphate induce
osteoblast differentiation accompanied by an increase
in differentiation markers such as ALP. We exam-
ined whether WEMV has any effect on osteoblast
differentiation of C2C12 or calvarial osteoblast cells
by measuring ALP activity. We found that WEMV
did not increase BMP-2-induced ALP activity or
decrease the viability of C2C12 cells, even at high
concentration (160 μg/mL) (Fig. 2a and b). We also
found that WEMV did not affect osteoblast differen-
tiation or viability of calvarial cells (Fig. 2c and d).
These results suggested that WEMV does not regu-
late the early stage of osteoblast differentiation and
proliferation.
Fig. 1 WEMV has a negative effect on osteoclastogenesis. BMMs were cultured for 4 days in differentiation medium containing WEMV at concentrations
of 20, 40, 80, and 160 μg/mL. a TRAP-positive stained cells were visualized using TRAP staining solution. b TRAP activity was measured by TRAP assay with
p-nitrophenyl phosphate as described in the Methods. c TRAP-positive stained MNCs were counted under an inverted microscope (40× magnification).
d Cell viability percentage were determined using a CCK assay after a 2-day incubation with the indicated concentrations of WEMV. e BMMs were cultured
in differentiation medium with WEMV (160 μg/mL) for the indicated numbers of days. TRAP-positive stained MNCs were counted on day 4. **p < 0.01
versus control
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WEMV suppresses NFATc1 and c-Fos expression in BMMs
To determine how WEMV suppresses osteoclastogene-
sis, we investigated c-Fos and NFATc1 expression.
BMMs pretreated with WEMV and control were further
incubated in osteoclast differentiation medium for vari-
ous time periods. c-Fos and NFATc1 mRNA and protein
levels increased markedly on days 1 and 2 in response to
RANKL stimulation (Fig. 3a and b), but WEMV almost
completely abolished their protein levels. WEMV re-
duced c-Fos mRNA level to 63 % on day 1 and NFATc1
mRNA level to 22 % on day 2 (p < 0.01) relative to con-
trol. Since NFATc1 is the master transcription factor that
regulates osteoclastogenesis, we investigated whether
ectopic NFATc1 expression could restore osteoclasto-
genesis that was suppressed by WEMV. BMMs were
infected with control retroviral vector or a recombinant
retroviral vector harboring a CA-NFATc1 and were then
cultured under osteoclast differentiation conditions.
WEMV completely inhibited MNC formation in BMMs
infected with the control vector, but did not inhibit
MNC formation in BMMs infected with CA-NFATc1
(Fig. 3c). As a counterpoint to the effect of WEMV on
NFATc1-inducing factors such as c-Fos, we investigated
the mRNA expression of v-Maf avian musculoaponeu-
rotic fibrosarcoma oncogene homolog B (MafB) and
inhibitor of DNA binding 2 (Id2), which are transcrip-
tional repressors of NFATc1 in BMMs. WEMV signifi-
cantly attenuated RANKL-induced downregulation of
MafB mRNA level to 76 % and increased Id2 mRNA
level by two fold on day 1 (p < 0.01) relative to the
control (Fig. 3b). These results indicated that the effect
of WEMV on osteoclastogenesis may involve the inhib-
ition of NFATc1 expression.
WEMV inhibits MAPK, NF-kB, and PLCγ2 activation in
BMMs
RANKL-RANK interaction activates early signaling
pathways, including MAPK and NF-kB signaling, to
regulate NFATc1 expression during osteoclastogenesis.
We further explored WEMV inhibition of early-stage of
osteoclast differentiation by examining the effect of
WEMV on RANKL-induced activation of MAPK and
NF-kB signaling. As shown in Fig. 4, RANKL increased
c-Jun N-terminal kinase (JNK) and p38 phosphorylation
markedly (lane 3) as well as I-kBα phosphorylation (lane
2) and degradation (lane 3). However, WEMV decreased
JNK phosphorylation (lane 7) and p38 phosphorylation
(lane 7) at 15 min relative to the control. In addition,
WEMV partially reduced I-kBα phosphorylation (lane 6)
at 5 min and impaired I-kBα degradation (lane 7 and 8)
at 15 and 30 min relative to the control. We next evalu-
ated whether WEMV affects Src-PLC-Ca2+ pathway to
regulate NFATc1 expression. WEMV markedly sup-
pressed RANKL-induced PLCγ2 phosphorylation (lane
6) at 5 min and Src phosphorylation (lane 7) at 15 min.
WEMV inhibits bone resorption activity of osteoclasts
To examine WEMV activity on bone resorption in a
physiologically relevant manner, mature osteoclasts ob-
tained from a BMCs-osteoblasts coculture system were
Fig. 2 WEMV does not affect osteoblast differentiation. C2C12 cells were cultured in differentiation medium with the indicated concentrations of
WEMV for 3 days. a ALP activity of C2C12 cells was determined using an ALP assay with naphthol AS-BI phosphate as described in the Methods.
b A CCK-8 assay was performed to determine the viability of C2C12 cells after a 2-day incubation with the indicated concentrations of WEMV.
Calvarial osteoblast cells were cultured in differentiation medium for 15 days. c ALP activity and (d) calvarial osteoblast cell viability were examined
after 15- and 2-day incubations, respectively
Shim et al. BMC Complementary and Alternative Medicine  (2016) 16:332 Page 5 of 10
Fig. 3 WEMV downregulates c-Fos and NFATc1 expression. BMMs were pretreated with WEMV (160 μg/mL) for 3 h and cultured in differentiation
medium for the indicated times as described in the Methods. Total RNA or protein was obtained at the indicated time points. a Total cell lysates
(30 μg) were separated by SDS-PAGE electrophoresis and transferred to PVDF membranes. Western blot analysis was performed with antibodies
specific for c-Fos (top), NFATc1 (middle), and β-actin (bottom). b qRT-PCR analysis of c-Fos, NFATc1, MafB, and Id2 was performed at the indicated time
points. Each mRNA level was normalized to that of HPRT. c BMMs were infected with retrovirus vector harboring GFP (control) or CA-NFATc1 in the
presence of polybrene (6 μg/mL) for 8 h. The infected cells were cultured in α-MEM medium containing puromycin (2 μg/mL) for 5 days and then
cultured in differentiation medium containing WEMV (160 μg/mL) for 4 days. TRAP-positive stained MNCs were counted after TRAP staining under an
inverted microscope (40× magnification). **p < 0.01 versus control. NS; not significance
Fig. 4 WEMV suppresses MAPK, NF-kB, and PLCγ signaling pathways. BMMs pretreated with WEMV (160 μg/mL) for 3 h were exposed to RANKL for
the indicated times. Total cell lysate (30 μg/mL) were separated by SDS-PAGE electrophoresis, transferred to PVDF membrane, and immunoblotted
with antibodies specific for each signaling pathway
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cultured with or without WEMV on a hydroxyapatite-
coated plate. As shown in Fig. 5a, RANKL treatment
stimulated mature osteoclasts to resorb on the plate.
However, WEMV substantially decreased the resorption
area without affecting the MNC number (Fig. 5b and c).
Quantitative analysis of the resorption area demon-
strated that WEMV concentrations of 80 μg/mL and
160 μg/mL significantly suppressed bone resorption
activity of osteoclasts to 12.56 ± 1.86 and 12.49 ± 1.37 %
(p < 0.05), respectively, relative to the control (17.46 ±
1.07 %). To delineate the molecular mechanism under-
lying the effect of WEMV on bone resorption, we exam-
ined whether WEMV affects the expression of TRAP,
ATPv0d2, and cathepsin K, all of which are involved in
bone resorption. We found that WEMV caused marked
downregulation of the mRNA levels of TRAP, ATP6v0d2,
and cathepsin K to 25, 39, and 20 % (p < 0.01), respect-
ively, relative to the control (Fig. 5d).
Discussion
M. verticillata seeds have been used in Asia for the
treatment of nephrolithiasis and cystolithiasis and for
enhancing kidney strength and reducing lower back and
bladder pain. The aim of this study was to evaluate the
pharmaceutical effect of WEMV on osteoclastogenesis
and osteogenesis. We showed that WEMV inhibited os-
teoclastogenesis by decreasing NFATc1 expression and
inhibited bone resorption by downregulating the expres-
sion of resorption markers, albeit at high concentration.
We found that WEMV suppressed osteoclast differen-
tiation (Fig. 1) and NFATc1 expression significantly
(Fig. 4). NFATc1 plays a crucial role in the regulation of
osteoclast transcription during osteoclastogenesis. Upon
RANKL stimulation, initiation and/or amplification of
NFATc1 expression is achieved mainly by the activation
of MAPK, NF-kB, and PLCγ-activated Ca2+ signaling
pathways [22] which subsequently activate key transcrip-
tion factors, activator protein 1 (AP-1), NFATc1, and
cAMP response element binding (CREB) [3]. These
RANKL-stimulated pathways are somewhat sequential
with respect to NFATc1 induction, but they cooperate in
the amplification of NFATc1 expression to regulate and
facilitate osteoclast-specific transcription. Our results
showed that WEMV inhibited the activation of MAPK,
Fig. 5 WEMV inhibits bone resorption. Osteoclasts with bone resorbing function were obtained from coculture of BMCs and calvarial osteoblasts. The
cells were seeded on an OsteoAssay Surface plate and cultured in differentiation medium containing WEMV (160 μg/mL) for 16 h. a MNCs (upper
panel) or the resorbed areas (lower panel) were photographed under an inverted microscope (40× magnification). b The percentage of resorbing
areas on the plate was quantified using Image J software. c TRAP-positive stained MNCs were counted to evaluate the cytotoxic effect of WEMV on
mature osteoclasts. d The mRNA levels of bone resorption genes (TRAP, ATPv0d2, and cathepsin K) were analyzed by qRT-PCR. *p < 0.05; **p < 0.01
versus control
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NF-kB, and PLCγ signaling as well as suppressed c-Fos
expression significantly (Figs. 3 and 4), suggesting that
WEMV inhibition to the upstream signaling cascade of
NFATc1 suppresses NFATc1 expression and osteoclasto-
genesis. Regarding distinct activation of these signaling
pathways for NFATc1 expression, different inhibitory
components present in WEMV might affect each signal-
ing pathway during osteoclastogenesis.
WEMV attenuated RANKL-induced downregulation
of MafB and Id2 significantly at days 1 and 2 accompan-
ied by suppression of NFATc1 expression (Fig. 3).
Transcription repressors, such as MafB and Id2, are
expressed abundantly in BMMs to interrupt the forma-
tion of transcriptional complex or the ability of com-
plexes to transcriptionally regulate NFATc1 expression
thereby preventing non-specific initiation of osteoclasto-
genesis and maintaining the potential of BMMs to differ-
entiate [23]. In response to RANKL or TNFα stimulation,
the expression of transcription repressors is downregu-
lated markedly within 48 h; however, their ectopic expres-
sion blocks osteoclastogenesis [24, 25]. Thus, WEMV
activity to maintain the expression of transcription repres-
sor may partially contribute to suppress NFATc1 expres-
sion and thus block osteoclastogenesis, although RANKL
stimulates osteoclast precursors.
Bone resorption requires high levels of resorption
markers such as TRAP, ATPv0d2, and cathepsin K, in
mature osteoclasts to degrade bone matrix. Inhibition of
bone resorption markers such as cathepsin K results in
decreased resorption activity by disrupting the intracel-
lular vesicle transport system that delivers degraded
collagen [26]. Our results showed that WEMV sup-
pressed either bone resorption or transcription of all of
the above marker genes significantly in osteoclasts with-
out affecting the MNC number (Fig. 5), suggesting that
WEMV may block either generation of resorbing protein
or vesicular trafficking system for bone resorption. With
respect to the inhibition of bone resorption and osteo-
clastogenesis by WEMV with no effect on osteoblast
differentiation or proliferation, an evaluation of the anti-
osteoporosis potential of WEMV alone or in combin-
ation with TCM stimulating osteogenesis in an in vivo
animal model system representing pathological bone
disorders would be of interest for a future study.
M. verticillata seeds contains several chemical constit-
uents, such as polysaccharides, fatty acid, flavonoid,
terpenes, and sterol [10]. Different polysaccharides, such
as MVS-I, MVS-IIA, or MVS-V, has been identified as
major polysaccharide in water extract of M. verticillata
seeds [27, 28]. Among them, arabinogalactan, a part
component of MVS-I or MVS-IIA, weakly inhibits
osteoclast differentiation of RAW264.7 cells (13.8 % in-
hibition at 100 μg/ml) by downregulating the expression
of TRAP and cathepsin K [29]. However, peptidoglycan,
other polysaccharides identified in water extract of M.
verticillata seeds, is known to have stimulatory effect on
osteoclast differentiation as well as bone resorption [30],
which should be avoided for anti-osteoclast agents.
Besides polysaccharide, M. verticillata seeds also have
oil constituents (11 % of total yield) including 16.18 %
palmitic, 7.7 % oleic, 61.6 %, linoleic, and 7.9 % stearic
acids [10]. We also identified the presence of fatty acid
(palmitic acid and oleamide) and sterol (β-sitosterol) in
WEMV by GC/MS analysis (data not shown). Regarding
the inhibitory activity of fatty acid and sterol on osteo-
clast differentiation, palmitic acid (50 % inhibition at
10 μg/ml) inhibits osteoclastogenesis by suppressing the
expression of fatty acid binding receptor, while oleamide
(150 % inhibition at 100 μM) suppresses bone resorption
by inhibiting gap junction of osteoclasts [31, 32]. In
addition, several terpenes and sterol (β-sitosterol; 15 %
inhibition at 1 μM) inhibit osteoclast differentiation by
inhibiting TRAP activity although the possible action
mechanism is unknown [33]. Thus, considering the
inhibitory activity of WEMV at high concentration, but
less amounts of identified components present in M.
verticillata seeds, it suggest that the inhibitory effect of
WEMV might result from the combined effect of these
chemical constituents such as polysaccharide, fatty acid
or sterol in WEMV rather the action of individual con-
stituents on osteoclast differentiation and resorption.
Since we identified the presence of some chemical
constituents as marker component for standardization
of WEMV (data not shown), further studies to
characterize the chemical properties of WEMV, to iden-
tify the unknown active components in WEMV, and to
elucidate its action mechanism on osteoclast differenti-
ation are needed to understand the effect of WEMV on
osteoclasts and the action mechanism.
WEMV specifically inhibited the osteoclast differenti-
ation potential of BMMs by inhibiting the RANKL
signaling pathway. In TCM, M. verticillata seeds has
been used to improve flow between the nutrient phase
and the defense phase that enhances kidney function.
Kidney has a function storing an essence of life, known
as kidney essence, which generates and nourishes bone
marrow to make a fullness of marrow in bone, forceful-
ness of musculoskeletal organ, and hardness of bone
[14]. When kidney essence is exhausted by aging or dis-
ease, kidney function to provide the nutrition in bone
marrow is insufficient to support bone microenviron-
ment that deteriorates musculoskeletal function and
increases pain in musculoskeletal organ, which is similar
to manifestations observed in pathological bone diseases,
such as osteoporosis and rheumatoid arthritis, caused by
an imbalance of bone remodeling. Several studies have
reported that herbs or herbal formulas originally used in
TCM to tonify kidney function have positive effects on
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bone metabolism by directly inhibiting osteoclast differ-
entiation [17] or resorption [34] or by regulating
osteoblast-dependent osteoclastogenesis [35]. Regulation
of the RANKL signaling on osteoclastogenesis has been
suggested as one of the mechanisms by which herbal
medicines tonifying kidney essence affect bone metabol-
ism [36]. Thus, WEMV inhibition of the RANKL signal-
ing pathway and bone resorption may be the molecular
mechanism by which WEMV affects bone metabolism in
addition to its pharmaceutic effect to strengthen kidney
function in TCM.
Conclusions
We have demonstrated that WEMV caused marked inhib-
ition of osteoclastogenesis by suppressing the RANKL sig-
naling axis and bone resorbing function by downregulating
bone resorption markers. This study reveals the molecular
mechanism underlying the effect of WEMV on osteoclasto-
genesis and suggests that WEMV may be a valid compo-
nent of therapeutic prescriptions used in TCM to treat
bone diseases caused by excess osteoclast differentiation
and bone resorption.
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